Case Study: Common Warts US Phase II

A 12-week study startup goal had been established by the sponsor of a Phase II multicenter efficacy and safety study on common warts, so sites were activated on a rolling basis to meet the first patient in (FPI) milestone. Working closely with the site teams and principal investigators, Novella adopted an aggressive strategy to increase the rate of enrollment. Novella Clinical not only increased the enrollment rate but beat projected timelines by five weeks.